Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Spin-Off Aims To Put Follow-On Biologics In The Clinic Within Two Years

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen products eyed as initial candidates, exec tells “The Pink Sheet” DAILY.
Advertisement

Related Content

CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana
CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen
Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen
Cell Therapeutics CEO James Bianco: An Interview With “The Pink Sheet” DAILY
Generic Biologics Bill From Waxman Offers Tax Incentives For Studies On Interchangeability

Topics

Advertisement
UsernamePublicRestriction

Register

PS065616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel